Cross class resistance to non beta lactams antimicrobials in | 17491
International Research Journals
Reach Us +44 330 818 7254

International Research Journal of Microbiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Cross class resistance to non beta lactams antimicrobials in extended spectrum beta lactamases producing Escherichia coli - a concern to health care practitioners


Thomas Benjamin Thoha, Agu Georgina, Musa Oluwaseunfunmi Sikirat, Adeyemi Michael Toyin, Odunsi Olayinka Davies, Adesoga Kehinde Omobowale and Ogueri Queeneth Chigozie

Extended Spectrum Beta lactamases are group of enzymes capable of Hydrolyzing the third generation cephalosporins thus rendering them ineffective for treatment. This study was carried out to determine the susceptibility profile of extended Spectrum Beta lactamases (ESBL) producing and non ESBL producing strains of E. coli. A total of 180 raw sewage samples were collected between September and December 2011 in Sagamu, Ogun State, Nigeria and were examined for the presence of Escherichia coli using standard Microbiology technique. The isolated Escherichia coli were later screened for production of extended Spectrum Beta lactamase enzyme using double disk synergy test method. Antimicrobial susceptibility patterns of both ESBL producing and non ESBL producing strains were evaluated using disk diffusion method. A total of 61(39.20%) strains of Escherichia coli were isolated from the samples. 20(32.8%) of the isolated Escherichia coli produced ESBL enzyme. Antimicrobial susceptibility studies performed on the twenty ESBL produces and twenty non ESBLs producers showed that the ESBL producers had significantly reduced susceptibility compared with the non ESBL producers with an alarming trend of associated resistance to gentamicin (75%), Nitrofurantion (70%), Erythromycin (70%), Ciprofloxacin (55%), Sulphamethoxazole (45%), Clindamycin (50%) and Amikacin (35%). Our findings confirm the cross class resistance to non Beta lactams antimicrobials in Extended spectrum Beta lactamases producing Escherichia coli. It is therefore very imperative for the clinicians to always request for the susceptibility test result of this isolate before the commencement of treatment.

Share this article